Modified virus boosts immunotherapy in kidney cancer trial
NCT ID NCT07510334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming normal cells, while the immunotherapy helps the immune system attack the cancer. The study aims to see if this combination leads to tumor shrinkage or stable disease, and monitors side effects. It is currently recruiting 18 adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer